IAS (r) available on the site https: //www.openhealth .fr / ias

Introduction
The IAS Respiratory Syndromes is based on the analysis of sales of "baskets" of drugs in pharmacies to suggest an impact on the Respiratory Syndromes in France
Following the study of a corpus of diagnoses and prescriptions carried out by general practitioners, it was concluded that the simultaneous prescription of paracetamol and a cough suppressant was the indicator with the best compromise between sensitivity and specificity. This indicator is not specific to a pathology but a proxy. It therefore reacts to other viral infections causing respiratory syndrome. We hypothesize that this IAS may also be a proxy indicator for uncomplicated forms of COVID-19, the main symptoms of which are fever, fatigue and dry cough.

Sources

OpenHealth The HUB - PHARMA: pharmacies pharmacies consumption data
Drug database source: SIPS THESORIMED
Source WHO ATC classification: WHO ATC Version 2020

Territory
Metropolitan France - excluding Corsica
Geographical breakdown: French administrative regions on 01/01/2016

Period
From 07/01/2014 to date

Market definition

Type: Human drug according to the WHO ATC class code assignments - version 2020 - from the source THESORIMED.

OMS ATC classes - version 2020 - included:

  • Class R05D "COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS"

  • Class R05X "OTHER COLD PREPARATIONS" - containing "PARACETAMOL" or "ACTIFED ETATS GRIPPAUX"

  • Class R06AD08 "oxomemazine"

  • Class R06AD09 "isothipendyl"

  • Class "paracetamol"

  • Class "paracetamol, combinations excl. psycholeptics"

The products are excluded:

  • whose "UCD Nature" field according to THESORIMED contains "AMPOULE (S)" or "POCHE (S)",

  • whose "Routes of administration" field according to THESORIMED contains "INJECTABLE".

Qualification of products for ticket counting: segmentation according to the assignment of products to an OMS ATC class code - version 2020 to date.

Did this answer your question?